Skip to main content
Allan Hackshaw on Muck Rack

Allan Hackshaw

As seen in: Nature, Human Reproduction Update, Memory Studies, MDPI, The BMJ, Cell Press, The Lancet, Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Allan

Contact Allan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

UK National Screening Committee position statement on surrogate outcomes in cancer screening trials

|
By Sarah Batson, Allan Hackshaw, Anne Mackie
| The BMJ Verified
Principles for appropriate use of surrogate outcomes in cancer screening Until better methods are available that account for the nuanced context of screening and go beyond simple correlations, we lack reliable tools to judge whether potential surrogates can truly replace mortality as the main outcome in screening trials.
Open in Who Shared Issue with article?

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study

|
By Anuradha Jayaram, Alison Reid, Francesco Orlando, Leila Zakka, Miriam Gonçalves, Constantine Alifrangis, Rob Jones Verified, Sarah H. Needleman, Diletta Bianchini, Anna Wingate, Kenrick Ng, Mark Linch, Ursula McGovern, John Staffurth, Simon J Crabb, Alison Birtle, Osvaldas Vainauskas, Gianmarco Leone, Allan Hackshaw, Andre Romualdo Lopes, André D. Lopes, Daniel Wetterskog, Francesca Demichelis, Gerhardt Attard, Memuna Rashid, Suparna Thakali, Jacqueline O’Dwyer, Elias Pintus, Susannah Brock, Millenn Chiwewe
| Nature Verified
Abstract The prognosis of newly diagnosed metastatic prostate cancer is highly variable. The primary objective of the PARADIGM prospective cohort study was to evaluate predictors of survival in blood collected at the start of each of the first six treatment cycles from 114 patients with high-volume metastatic prostate cancer (biologically male) who were starting androgen deprivation therapy in combination with docetaxel or an androgen receptor pathway inhibitor.
Open in Who Shared Issue with article?

Thymic health and immunotherapy outcomes in patients with cancer

|
By Simon Bernatz, Vasco Prudente, Suraj Pai, Asbjørn K. Attermann, Alessandro Di Federico, Andrew Rowan Verified, Selvaraju Veeriah, Lars Dyrskjøt, Leonard Nürnberg, Joao V Alessi, Patrick A. Ott, Elad Sharon, Allan Hackshaw, Nicholas McGranahan, Christopher Abbosh, Raymond Mak, Danielle S Bitterman, Mark Awad, Biagio Ricciuti, Charles Swanton, Mariam Jamal-Hanjani, Nicolai J. Birkbak, Hugo J. W. L. Aerts
| Nature Verified
Abstract Although immunotherapy has revolutionized cancer treatment, many patients still experience limited benefit, highlighting the urgent need for improved biomarkers1. Although immunotherapy is founded on unleashing T cells2, most existing biomarkers remain tumour-centric and mainly overlook host immune competence. The thymus is a key immune organ that is crucial for T cell maturation, and we hypothesized that thymic functionality is associated with immunotherapy outcomes3.
Open in Who Shared Issue with article?
See all 34 licensed articles (35 Total)